Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07904429
PHASE3

Keverprazan-Minocycline Dual Therapy of Different Durations Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication.

Sponsor: Nanjing First Hospital, Nanjing Medical University

View on ClinicalTrials.gov

Summary

This study aims to compare the efficacy and safety of keverprazan-minocycline dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication, focusing on eradication rates, patient adherence, and the incidence of adverse drug reactions.

Official title: Efficacy and Safety of Keverprazan-minocycline Dual Therapy With Different Treatment Durations Versus Bismuth-based Quadruple Therapy for Helicobacter Pylori Eradication: an Open-label, Multicenter, Randomized, Non-inferiority Trial.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

612

Start Date

2026-07-15

Completion Date

2027-12-30

Last Updated

2026-10-29

Healthy Volunteers

No

Interventions

DRUG

Minocycline

100 mg oral capsule, twice daily

DRUG

Keverprazan

20 mg oral tablet, twice daily

DRUG

Amoxicillin

1000 mg oral tablet, twice daily

DRUG

Colloidal Bismuth Pectin

300 mg oral preparation, twice daily

Locations (1)

Nanjing First Hospital

Nanjing, Jiangsu, China